Dr.Reddy's Laboratories Ltd (REDY.BO)
|Market Cap (Mil.):||Rs467,399.31|
|Shares Outstanding (Mil.):||170.34|
Reuters Market Eye - Shares of Dr. Reddy's Laboratories rise, adding to Friday's 1.8 percent gain, after the drugmaker's annual report last week provided key details about spending on building capacity, raising hopes that expenses would reduce after FY16, dealers say.
* Shares of India's Dr. Reddy's Laboratories up 1 percent, adding to Friday's 1.8 percent gain, after the drugmaker's annual report last week provided key details about spending on building capacity, raising hopes that expenses would reduce after FY16, dealers say. * Dr. Reddy's said in its annual report filed with the U.S. Securities and Exchange Commission that the company would finance expansion plans through operating cash flow and through cash and other investments, and that the majority of
* Shares in Indian drugmakers fall, with Dr Reddy's Laboratories down 1.9 percent, on concerns that sales in Russia and Ukraine will be hit given military tensions between the two countries. * Dr. Reddy's has the highest exposure to Russia and former Soviet republics, with the region comprising 14.5 percent of sales, Bank of America-Merrill Lynch says in a note dated on Monday. * Ranbaxy Laboratories Ltd and Glenmark Pharmaceuticals Ltd also have exposure to Russia and former Soviet republics,
Reuters Market Eye - Shares in Dr Reddy's Laboratories rose as much as 2.1 percent to a record high on growing hopes about its U.S. business.